Incyte Corp. (INCY)

80.54
NASDAQ : Health Technology
Prev Close 81.31
Day Low/High 80.23 / 82.26
52 Wk Low/High 57.00 / 89.30
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 214.44M
Market Cap 17.44B
EPS 0.50
P/E Ratio 69.50
Div & Yield N.A. (N.A)

Latest News

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Incyte Announces Positive Results From A Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte Announces Positive Results From A Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte (Nasdaq:INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75...

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Pemigatinib As A First-Line Therapy For Cholangiocarcinoma

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Pemigatinib As A First-Line Therapy For Cholangiocarcinoma

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with...

New Data From GEOMETRY Mono-1 Study Show Clinically Meaningful Results In Patients With Non-Small Cell Lung Cancer With MET Exon-14 Skipping Mutation Treated With Capmatinib

New Data From GEOMETRY Mono-1 Study Show Clinically Meaningful Results In Patients With Non-Small Cell Lung Cancer With MET Exon-14 Skipping Mutation Treated With Capmatinib

Incyte (Nasdaq:INCY) today announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.

FDA Approves Jakafi® (ruxolitinib) For The Treatment Of Patients With Acute Graft-Versus-Host Disease

FDA Approves Jakafi® (ruxolitinib) For The Treatment Of Patients With Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the U.S.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 40 th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho Palos Verdes.

Data From Incyte's Inflammation And Autoimmunity Portfolio To Be Featured At The 24th World Congress Of Dermatology

Data From Incyte's Inflammation And Autoimmunity Portfolio To Be Featured At The 24th World Congress Of Dermatology

Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24 th World Congress of Dermatology (WCD).

Incyte Announces Abstracts Accepted For Presentation At The 2019 ASCO Annual Meeting And The 24th Congress Of EHA

Incyte Announces Abstracts Accepted For Presentation At The 2019 ASCO Annual Meeting And The 24th Congress Of EHA

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at 8:40 am (PDT) in Las Vegas; UBS Global...

Incyte Reports 2019 First Quarter Financial Results And Provides Updates On Key Clinical Programs

Incyte Reports 2019 First Quarter Financial Results And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2019 first quarter financial results and provides a status update on the Company's development portfolio.

Incyte Expected to Earn 29 Cents a Share

Incyte Expected to Earn 29 Cents a Share

Incyte revenue expected to rise 27.7% to $488 million.

Incyte To Report First Quarter Financial Results

Incyte To Report First Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its first quarter 2019 financial results conference call and webcast for 8:00 a.

The New #18 Most Shorted Nasdaq 100 Component: Incyte

The New #18 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Incyte Joins Patient Organizations Worldwide In Recognizing Rare Disease Day 2019

Incyte Joins Patient Organizations Worldwide In Recognizing Rare Disease Day 2019

Incyte Corporation (Nasdaq:INCY) announced today that it has again joined with the National Organization for Rare Disorders (NORD), the European Organizations for Rare Diseases and other health organizations and advocates in recognizing Rare Disease Day...

Data From Incyte's Cancer Research Portfolio To Be Featured In Seven Abstracts At The AACR Annual Meeting 2019

Data From Incyte's Cancer Research Portfolio To Be Featured In Seven Abstracts At The AACR Annual Meeting 2019

Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019 at 12:00 pm (EDT) in Boston; and...

Incyte Reports 2018 Fourth Quarter And Year-End Financial Results, Provides 2019 Financial Guidance And Provides Updates On Key Clinical Programs

Incyte Reports 2018 Fourth Quarter And Year-End Financial Results, Provides 2019 Financial Guidance And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company's development portfolio.

Incyte Expected to Earn 17 Cents a Share

Incyte Expected to Earn 17 Cents a Share

Incyte revenue expected to rise 9.5% to $486.2 million.

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALGT, ANGI, BHE, GRA, HPJ, INCY, KN, LND, MLAB, NR, TDC, TZOO, VLY Downgrades: ASYS, DX, FFG, HAS Initiations: FSCT Read on to get TheStreet Quant Ratings' detailed report:

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis

INDIANAPOLIS, Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and...

Incyte To Report Fourth Quarter And Year-end Financial Results

Incyte To Report Fourth Quarter And Year-end Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD).

The New #24 Most Shorted Nasdaq 100 Component: Incyte

The New #24 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 12/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte Climbs on Guggenheim Upgrade

Incyte Climbs on Guggenheim Upgrade

Shares of Incyte Corporation climbed Thursday after Guggenheim Partners upgraded the biopharmaceutical company from nuetral to buy.

TheStreet Quant Rating: C+ (Hold)